| Literature DB >> 26330877 |
Kourosh Goudarzipour1, Farid Ghazizadeh1, Hesameddin Hoseini Tavassol1, Behdad Behnam2.
Abstract
An important complication of chemotherapy is thromboembolic events that can occur during treatment course. In this way, Warfarin can be used as an efficient prophylactic agent to prevent these complications. Although bleeding is a common adverse effect of Warfarin, eosinophilia is a rare side effect of this drug. We have reported a 5-year-old boy with Burkitt lymphoma who underwent chemotherapy. In the course of chemotherapy, because of thrombosis of the left jugular vein, we initiated Warfarin as a prophylactic drug for TEE secondary to chemotherapy. Following Warfarin initiation, eosinophilia appeared and subsequent to cessation of drug, eosinophilia disappeared. This case is presented to point out physicians to consider eosinophilia as a rare adverse-effect of Warfarin and monitor blood cell differentiation regularly during the course of treatment with this drug.Entities:
Keywords: Anticoagulant therapy; Burkitt lymphoma; Eosinophilia; Pediatrics; Warfarin
Year: 2015 PMID: 26330877 PMCID: PMC4518117
Source DB: PubMed Journal: Iran J Pharm Res ISSN: 1726-6882 Impact factor: 1.696